Survival after biventricular mechanical circulatory support: Does the type of device matter?

Kirsch, Matthias; Mazzucotelli, Jean‐Philippe; Roussel, Jean‐Christian; Bouchot, Olivier; Nloga, J.; Leprince, Pascal; Litzler, Pierre‐Yves; Vincentelli, André; Mécanique, Groupe de Réflexion sur l'Assistance

doi:10.1016/j.healun.2011.11.024

Cited by 51 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other groups have similarly stressed the low risk of thromboembolism in patients supported with the SynCardia t-TAH [10,12]. Furthermore, the recent report from the GRAM registry showed that SynCardia t-TAH recipients experienced significantly fewer neurologic events than BiVAD recipients [15]. This might be related to the nearly complete removal of the native heart cavities, the lack of inflow grafts, and the use of short, large diameter outflow grafts in CardioWest TAH recipients.…”

Section: Commentmentioning

confidence: 97%

“…Among the various devices available to support patients with biventricular failure, the SynCardia t-TAH is used less frequently than paracorporeal BiVADs. Thus, according to the latest INTERMACS [14] and the French GRAM Registry [15] reports, the SynCardia t-TAH was used, respectively, in 21% (99 of 467) and in 24% (90 of 383) of patients requiring biventricular support. Data comparing outcomes with various biventricular support devices are scarce.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation

SynCardia Temporary Total Artificial Heart as Bridge to Transplantation: Current Results at La Pitié Hospital

Kirsch

Nguyen

Mastroianni

et al. 2013

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 97%

Section: Commentmentioning

confidence: 99%

SynCardia Temporary Total Artificial Heart as Bridge to Transplantation: Current Results at La Pitié Hospital

Kirsch

Nguyen

Mastroianni

et al. 2013

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

“…Therefore, a larger patient group presenting with different comorbidity and clinical characteristics is needed to assess the suitability of Freedom driver along with CW-TAH for destination therapy. However, the pneumatic drivelines passing through the skin to the exterior to deliver and withdraw driving compressed air to the implanted moving diaphragms were reported as a source of infection in one-third of the patients in the study by Torregrossa et al A French study also reported the same findings in the patients supported for more than a year [12]. These data highlight the need for maintaining a high suspicion for infections in patients supported for the long term on a SynCardia TAH besides developing new systems to power implanted driving units which are fully operational without interruption of skin barriers in order to decrease the risk of infections.…”

Section: Discussionmentioning

confidence: 81%

“…Although LVAD has established itself as a successful BTT, but in cardiac pathologies where LVAD is contraindicated, including biventricular failure, intractable arrhythmias, irreparable ventricular anatomical defects, mechanical prosthetic valve replacement, and cardiac neoplasms, the dominance of TAH over LVAD is undisputable. Moreover, the design of TAH offers several advantages relative to present continuous flow LVADs, like reduced thrombosis and stroke rates, reduced after load and preload sensitivity, and a reduction in device-induced bleeding [12].…”

Section: Discussionmentioning

confidence: 99%

Total Artificial Heart as the Destination Therapy: A Review

Minhas¹

2017

AJCTS

View full text Add to dashboard Cite

Introduction: For the patients awaiting cardiac transplantation, mechanical circulatory support has been widely utilized in the form of left ventricular assist device or total artificial heart. Both total artificial heart and left ventricular assist device have been approved for the use as a bridge to transplantation therapy; however only left ventricular assist device has been approved for use as the destination therapy. The purpose of this review is to establish, using this literature, the possibility for the artificial heart transplant to be used as destination therapy besides highlighting the recent developments in this area of research in order to narrate the future of artificial heart transplantation.

show abstract

“…2,3 Among patients with advanced heart failure, those with biventricular failure have the worst prognosis and very few available options while waiting for a compatible donor. They are usually more fragile preoperatively, with more comorbidities, including renal and hepatic dysfunction, than patients receiving sole left ventricular support.…”

Section: Discussionmentioning

confidence: 99%

Experience with the SynCardia total artificial heart in a Canadian centre

Nguyen

Pellerin

Perrault

et al. 2017

CJS

View full text Add to dashboard Cite

Background:The SynCardia total artificial heart (TAH) provides complete circulatory support by replacing both native ventricles. Accepted indications include bridge to transplantation and destination therapy. We review our experience with TAH implantation during a period when axial flow pump became available. Methods:We retrospectively analyzed the demographics, clinical characteristics and survival of all patients receiving the TAH. Results:From September 2004 to November 2016, 13 patients (12 men, mean age 45 ± 13 yr) received the TAH for refractory cardiogenic shock secondary to idiopathic (56%) or ischemic (17%) cardiomyopathy and to other various causes (33%). Before implantation, mean ejection fraction was 14% ± 4%, 7 (54%) patients had previous cardiac surgery, 4 (31%) were on mechanical ventilation, and 3 (23%) patients were on dialysis. The mean duration of TAH support was 46 ± 40 days. Three (23%) patients died while on support after a mean of 15 days. Actuarial survival on support was 77% ± 12% at 30 days after implantation. Complications on support included stroke (n = 1, 8%), acute respiratory distress syndrome requiring prolonged intubation (n = 5, 38%) and acute renal failure requiring temporary dialysis (n = 5, 38%). Ten (77%) patients survived to be transplanted after a mean of 52 ± 42 days of support. Actuarial survival rates after transplant were 67% ± 16% at 1 month and 56% ± 17% at 1 year after transplantation. Conclusion:The TAH provides an alternative with low incidence of neurologic events in extremely fragile and complex patients waiting for heart transplantation. Complex and unusual anatomic conditions explained the current use of TAH.

show abstract

Survival after biventricular mechanical circulatory support: Does the type of device matter?

Cited by 51 publications

References 18 publications

SynCardia Temporary Total Artificial Heart as Bridge to Transplantation: Current Results at La Pitié Hospital

SynCardia Temporary Total Artificial Heart as Bridge to Transplantation: Current Results at La Pitié Hospital

Total Artificial Heart as the Destination Therapy: A Review

Experience with the SynCardia total artificial heart in a Canadian centre

Contact Info

Product

Resources

About